title: Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.
abstract: BACKGROUND
  Uveal melanoma (UM) is a disease that affects approximately five people per million in the United States. This disease metastasises predominantly to the liver, and treatment options following the clinical detection of these sequelae are limited. Vascular endothelial growth factor-A (VEGF-A) is the primary activator of tumour angiogenesis and functions by binding to VEGF-Receptor 2 (VEGF-R2) and is often required for tumour growth beyond 2-3 mm. The purpose of this study was to investigate the expression of VEGF-A and the primary VEGF-R2 in three UM cell lines. Furthermore, we investigated the effects of VEGF-A inhibition on receptor activation and production of other cytokines. Finally, the effects of VEGF-A inhibition on the proliferation, migration, and invasion in the cell lines were ascertained.
  
  
  METHODS
  Three UM cell lines (92.1, OCM-1, and UW-1) were incubated with and without the addition of 100 μg/mL of bevacizumab. VEGF-A expression under both conditions was determined by sandwich enzyme-linked immunosorbent assay (ELISA), and phosphorylated VEGF-R2 expression was determined using western blot. The effects of VEGF-A inhibition on 20 cytokines (IL-1a, IL-2, IL-5, IL-8, IL-12p70, GM-CSF, IFNy, CCL3, MMP-9, TNF-a, IL-1b, IL-4, IL-6, IL-10, IL-13, GRO, MCP-1, MIP-1b, and RANTES) were determined using a multiplex sandwich ELISA. Proliferation rates before and after treatment were evaluated via sulforhodamine B assay, and migration and invasion assays implementing the Boyden chamber technique, the latter with artificial extracellular matrix, were used to assess their respective abilities. The Student's t-test was used to compare changes in cytokine expression following VEGF-A inhibition. Analysis of variance was used to compare changes in the functional abilities of three uveal melanoma cell lines following VEGF-A inhibition. A P-value < 0.05 was considered statistically significant.
  
  
  RESULTS
  All three cell lines produced copious amounts of VEGF-A in culture (92.1, 11785.5 ± 231.8 pg/μL; OCM-1, 4608.0 ± 324.0 pg/μL; UW-1, 8309.3 ± 634.5 pg/μL), which was reduced to undetectable levels following the administration of bevacizumab (P< 0.05). Similarly, detectable phosphorylated VEGF-R2 was present in all cells, which was reduced significantly in all cell lines following bevacizumab treatment (107525.2 ± 8602.0 versus 1024.5 ± 98.2, 46587.3 ± 4192.9 versus 12821.1 ± 1666.7, and 60394.3 ± 4026.4 versus 6908.2 ± 607.2; 92.1, OCM-1, and UW-1, respectively; P< 0.05). Of the cytokines investigated, only MMP-9 and CCL3 were ubiquitously altered across all three cell lines following bevacizumab treatment; they were upregulated (CCL3: 1072.50 ± 18.77 pg/mL versus 1281.00 ± 72.34 pg/mL; 22.5 ± 7.85 pg/mL versus 62.00 ± 9.16 pg/mL; 20.33 ± 6.35 pg/mL versus 35.00 ± 6.22 pg/mL; control versus bevacizumab; MMP-9: 25.50 ± 5.47 pg/mL versus 88.25 ± 13.38 pg/mL; 19.75 ± 4.14 pg/mL versus 45.25 ± 8.36 pg/mL; 3.25 ± 1.09 pg/mL versus 19.25 ± 3.77 pg/mL; control versus bevacizumab; 92.1, OCM-1, and UW-1, respectively; P< 0.05). Bevacizumab significantly reduced the proliferation of one cell line (92.1: 0.405 ± 0.012 versus 0.509 ± 0.033; bevacizumab versus control; values OD; P< 0.05), the migration of two cell lines (92.1: 0.071 ± 0.003 versus 0.115 ± 0.003; OCM-1: 0.049 ± 0.005 versus 0.117 ± 0.014; bevacizumab versus control; values OD; P< 0.05), and did not significantly affect invasion.
  
  
  CONCLUSIONS
  Despite the significant reduction in phosphorylated VEGF-R2 levels, bevacizumab did not have a dramatic impact on the functional abilities of the three UM cell lines studied. Our results indicate that compensatory mechanisms, such as the upregulation of MMP-9 and CCL-3, following bevacizumab administration may mitigate its effects on these abilities.
authors.affiliation: The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec H3A 2B4, Canada.
authors.forename: Patrick
authors.initials: P
authors.lastname: Logan
authors.forename: Julia
authors.initials: J
authors.lastname: Burnier
authors.forename: Miguel N
authors.initials: MN
authors.lastname: Burnier
keywords: VEGF-A; bevacizumab; invasion; migration; proliferation; uveal melanoma
references.citation: Pathobiology. 2004;71(5):241-5
references.pmid: 15459482
references.citation: Am J Ophthalmol. 2004 Dec;138(6):936-51
references.pmid: 15629284
references.citation: Am J Ophthalmol. 1978 Jul;86(1):76-80
references.pmid: 677236
references.citation: Eur J Surg Oncol. 2009 Nov;35(11):1192-7
references.pmid: 19329272
references.citation: Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1414-21
references.pmid: 11381040
references.citation: Indian J Ophthalmol. 2011 May-Jun;59(3):191-6
references.pmid: 21586838
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: Arch Ophthalmol. 2006 Oct;124(10):1428-34
references.pmid: 17030710
references.citation: Nucleic Acids Res. 2001 May 1;29(9):e45
references.pmid: 11328886
references.citation: Arch Ophthalmol. 1995 Nov;113(11):1462-3
references.pmid: 7487612
references.citation: Cancer. 1983 Jul 15;52(2):334-6
references.pmid: 6190546
references.citation: Br J Ophthalmol. 2011 Jan;95(1):112-7
references.pmid: 20819828
references.citation: Asian J Androl. 2012 Sep;14(5):745-51
references.pmid: 22705563
references.citation: Mol Cancer Ther. 2007 Oct;6(10):2664-74
references.pmid: 17938260
references.citation: Cancer Res. 2009 Apr 1;69(7):3077-85
references.pmid: 19293190
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: Ophthalmology. 2011 Jan;118(1):176-83
references.pmid: 20673589
references.citation: Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
references.pmid: 18432654
references.citation: Ophthalmology. 2006 Oct;113(10):1695.e1-15
references.pmid: 17011951
references.citation: Br J Ophthalmol. 2002 Apr;86(4):448-52
references.pmid: 11914216
references.citation: J Pathol. 2001 Jun;194(2):201-6
references.pmid: 11400149
references.citation: J Pathol. 1998 Jan;184(1):53-7
references.pmid: 9582527
references.citation: J Exp Med. 1971 Feb 1;133(2):275-88
references.pmid: 4332371
references.citation: J Natl Cancer Inst. 1995 Apr 5;87(7):506-16
references.pmid: 7707437
references.citation: Int J Cancer. 2006 Apr 15;118(8):1869-76
references.pmid: 16284949
references.citation: Mol Vis. 2008 Sep 05;14:1614-22
references.pmid: 18776949
references.citation: Invest Ophthalmol Vis Sci. 2010 May;51(5):2329-37
references.pmid: 20042655
references.citation: Histopathology. 2012 Apr;60(5):740-7
references.pmid: 22296176
references.citation: Drugs Today (Barc). 2011 Sep;47(9):669-81
references.pmid: 21971541
references.citation: Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5445-51
references.pmid: 20538984
references.citation: Ophthalmology. 2003 May;110(5):962-5
references.pmid: 12750098
references.citation: Curr Eye Res. 1997 May;16(5):487-95
references.pmid: 9154388
references.citation: Melanoma Res. 2005 Jun;15(3):141-5
references.pmid: 15917694
references.citation: Cancer Treat Rev. 2012 Aug;38(5):549-53
references.pmid: 22270078
references.citation: Life Sci. 2003 Sep 26;73(19):2413-20
references.pmid: 12954450
references.citation: Mol Biol Cell. 1993 Dec;4(12):1317-26
references.pmid: 8167412
references.citation: Cell Mol Immunol. 2004 Apr;1(2):95-104
references.pmid: 16212895
references.citation: Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6
references.pmid: 15203102
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Cancer Res. 2002 Feb 1;62(3):854-9
references.pmid: 11830543
references.citation: Rocz Akad Med Bialymst. 2004;49 Suppl 1:155-8
references.pmid: 15638406
references.citation: N Engl J Med. 2006 Oct 5;355(14):1409-12
references.pmid: 17021315
references.citation: Br J Ophthalmol. 2000 Jul;84(7):750-6
references.pmid: 10873988
references.citation: Nat Rev Cancer. 2006 Aug;6(8):626-35
references.pmid: 16837971
references.citation: Br J Ophthalmol. 2002 Apr;86(4):440-7
references.pmid: 11914215
references.citation: Cornea. 2011 Oct;30(10):1071-7
references.pmid: 21775887
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2835-42
references.pmid: 20089875
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136
references.citation: Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):985-93
references.pmid: 15891893
references.citation: Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1047-57
references.pmid: 19029025
references.citation: Int J Cancer. 1995 Jul 17;62(2):155-61
references.pmid: 7622289
references.citation: Cancer Res. 2008 Jun 1;68(11):4392-7
references.pmid: 18519701
references.citation: Invest Ophthalmol Vis Sci. 2010 May;51(5):2388-92
references.pmid: 20007836
references.citation: Br J Ophthalmol. 2009 Aug;93(8):1042-6
references.pmid: 19429579
references.citation: Cancer. 1974 Oct;34(4):1001-4
references.pmid: 4424282
references.citation: Ophthalmology. 2003 May;110(5):956-61
references.pmid: 12750097
references.citation: Biol Pharm Bull. 2011;34(12):1785-8
references.pmid: 22130231
references.citation: Melanoma Res. 1999 Oct;9(5):445-50
references.pmid: 10596910
references.citation: Am J Ophthalmol. 1998 Jun;125(6):779-96
references.pmid: 9645716
references.citation: Clin Cancer Res. 2012 Feb 1;18(3):654-65
references.pmid: 22228632
references.citation: JAMA. 1988 Aug 19;260(7):974-6
references.pmid: 3398202
references.citation: Curr Eye Res. 2011 Apr;36(4):386-90
references.pmid: 21284506
references.citation: Br J Cancer. 2011 Apr 12;104(8):1270-7
references.pmid: 21407219
references.citation: Cell Signal. 2007 Oct;19(10):2003-12
references.pmid: 17658244
references.citation: Exp Cell Res. 2006 Mar 10;312(5):549-60
references.pmid: 16336962